{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Gusperimus_Trihydrochloride",
  "nciThesaurus": {
    "casRegistry": "84937-45-1",
    "chebiId": "",
    "chemicalFormula": "C17H37N7O3.3HCl",
    "definition": "A derivative of the antitumor antibiotic spergualin with immunosuppressant activity.  Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines.",
    "fdaUniiCode": "QZS4144IO0",
    "identifier": "C1598",
    "preferredName": "Gusperimus Trihydrochloride",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C574"
    ],
    "synonyms": [
      "(+-)-15-Deoxyspergualin",
      "1-Amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione",
      "15-Deoxyspergualin",
      "15-Deoxyspergualin Hydrochloride",
      "7-[(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amnio]-1-hydroxy-2-oxoethyl]heptanamide",
      "BMS-181173",
      "BMY-42215-1",
      "DSG",
      "Deoxyspergualin",
      "Deoxyspergualin Hydrochloride",
      "GUSPERIMUS TRIHYDROCHLORIDE",
      "Gusperimus Trihydrochloride",
      "N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-7-guanidinoheptanamide",
      "NKT-01",
      "Spanidin"
    ]
  }
}